{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:36:58Z","timestamp":1767033418888,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.110198","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T12:43:41Z","timestamp":1597668221000},"page":"110198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["It is time to drop hydroxychloroquine from our COVID-19 armamentarium"],"prefix":"10.1016","volume":"144","author":[{"given":"Tarek","family":"Kashour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad M.","family":"Tleyjeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mehy.2020.110198_b0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.mehy.2020.110198_b0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.mehy.2020.110198_b0015","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2020.110198_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101735","article-title":"Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review","volume":"35","author":"Hashem","year":"2020","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"10.1016\/j.mehy.2020.110198_b0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.mehy.2020.110198_b0030","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"105949","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.110198_b0035","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.9184","article-title":"Prescription fill patterns for commonly used drugs dring the COVID-19 pandemic in the United States","author":"Vaduganathan","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2020.110198_b0040","unstructured":"Elizabeth Cohen WB. US stockpile stuck with 63 million doses of hydroxychloroquine. https:\/\/edition.cnn.com\/2020\/06\/17\/health\/hydroxychloroquine-national-stockpile\/index.html. Accessed."},{"key":"10.1016\/j.mehy.2020.110198_b0045","first-page":"2015","article-title":"Effect of hydroxychloroquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial","volume":"2020","author":"Horby","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.mehy.2020.110198_b0050","article-title":"Hydroxychloroquine for early treatment of adults with mild COVID-19: A randomized-controlled trial","author":"Mitj\u00e0","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2020.110198_b0055","doi-asserted-by":"crossref","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: A randomized trial","author":"Skipper","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mehy.2020.110198_b0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19","author":"Boulware","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110198_b0065","first-page":"2020","article-title":"A cluster-randomized trial of hydroxychloroquine as prevention of COVID-19 transmission and disease","volume":"2020","author":"Mitja","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.mehy.2020.110198_b0070","first-page":"2012","article-title":"Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis","volume":"2020","author":"Kashour","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.mehy.2020.110198_b0075","first-page":"2016","article-title":"The cardiac toxicity of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-regression analysis","volume":"2020","author":"Tleyjeh","year":"2020","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0080","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3904\/kjim.2020.157","article-title":"In vitro activity of lopinavir\/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses","volume":"35","author":"Kang","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.mehy.2020.110198_b0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virology Journal"},{"issue":"8","key":"10.1016\/j.mehy.2020.110198_b0090","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.mehy.2020.110198_b0095","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.mehy.2020.110198_b0100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","volume":"20","author":"To","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mehy.2020.110198_b0105","doi-asserted-by":"crossref","unstructured":"Browning DJ. Pharmacology of chloroquine and hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy. New York, NY: Springer New York; 2014:35-63.","DOI":"10.1007\/978-1-4939-0597-3_2"},{"key":"10.1016\/j.mehy.2020.110198_b0110","first-page":"139","article-title":"Possible mechanisms of action of antimalarials in rheumatic disease","volume":"44","author":"Cutler","year":"1993","journal-title":"Agents Actions Suppl"},{"key":"10.1016\/j.mehy.2020.110198_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa623","article-title":"Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients","author":"Fan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.mehy.2020.110198_b0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cpt.1856","article-title":"Optimizing hydroxychloroquine dosing for patients With COVID-19: An integrative modeling approach for effective drug repurposing","volume":"108","author":"Garcia-Cremades","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0135","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0149-2918(95)80039-5","article-title":"Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1","volume":"17","author":"Sperber","year":"1995","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.mehy.2020.110198_b0140","first-page":"1874","article-title":"Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis\u2013a cross sectional study","volume":"20","author":"Tett","year":"1993","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.mehy.2020.110198_b0145","first-page":"1604","article-title":"Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?","volume":"33","author":"Cunha","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.mehy.2020.110198_b0150","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.200493","article-title":"Hydroxychloroquine in patients with rheumatic disease complicated by COVID-19: Clarifying target exposures and the need for clinical trials","author":"Balevic","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.mehy.2020.110198_b0155","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa394","article-title":"Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients","author":"Perinel","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.mehy.2020.110198_b0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-Infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.mehy.2020.110198_b0165","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","author":"Hadjadj","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.mehy.2020.110198_b0170","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1096\/fj.202000919","article-title":"Rethinking the role of hydroxychloroquine in the treatment of COVID-19","volume":"34","author":"Meyerowitz","year":"2020","journal-title":"Faseb J"},{"issue":"3","key":"10.1016\/j.mehy.2020.110198_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212614","article-title":"Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction","volume":"14","author":"Miranda","year":"2019","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.mehy.2020.110198_b0180","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cvr\/cvz013","article-title":"A current understanding of drug-induced QT prolongation and its implications for anticancer therapy","volume":"115","author":"Roden","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0185","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","article-title":"Drug-induced long QT syndrome","volume":"62","author":"Kannankeril","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.mehy.2020.110198_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2020.05.030","article-title":"Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine\/hydroxychloroquine for treating COVID-19","author":"Uzelac","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.mehy.2020.110198_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2020.04.045","article-title":"Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans","author":"Giudicessi","year":"2020","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.mehy.2020.110198_b0200","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for Coronavirus Disease 19 (COVID-19)","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0205","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.mayocp.2013.01.013","article-title":"Institution-wide QT alert system identifies patients with a high risk of mortality","volume":"88","author":"Haugaa","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.mehy.2020.110198_b0210","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/CCM.0b013e318232db4a","article-title":"High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study","volume":"40","author":"Pickham","year":"2012","journal-title":"Crit Care Med"},{"issue":"11","key":"10.1016\/j.mehy.2020.110198_b0215","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1096\/fj.201700255R","article-title":"Hypoxia reduces mature hERG channels through calpain up-regulation","volume":"31","author":"Lamothe","year":"2017","journal-title":"Faseb j"},{"issue":"9","key":"10.1016\/j.mehy.2020.110198_b0220","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.5665\/sleep.6080","article-title":"Patients with obstructive sleep apnea have cardiac repolarization disturbances when travelling to altitude: Randomized, placebo-controlled trial of acetazolamide","volume":"39","author":"Latshang","year":"2016","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.mehy.2020.110198_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199028","article-title":"QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications","volume":"13","author":"Fernandes","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0230","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jat.3447","article-title":"Assessment of temperature-induced hERG channel blockade variation by drugs","volume":"37","author":"Kauthale","year":"2017","journal-title":"J Appl Toxicol"},{"issue":"12","key":"10.1016\/j.mehy.2020.110198_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208321","article-title":"Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation","volume":"13","author":"Aromolaran","year":"2018","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.mehy.2020.110198_b0240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/jpp.JPP_158_17","article-title":"Investigation of hERG1b influence on hERG channel pharmacology at physiological temperature","volume":"9","author":"El Harchi","year":"2018","journal-title":"J Pharmacology Pharmacotherapeutics"},{"issue":"3","key":"10.1016\/j.mehy.2020.110198_b0245","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"20","key":"10.1016\/j.mehy.2020.110198_b0250","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mehy.2020.110198_b0255","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.115.003560","article-title":"Azithromycin causes a novel proarrhythmic syndrome","volume":"10","author":"Yang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.mehy.2020.110198_b0260","first-page":"2008","article-title":"Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study","volume":"2020","author":"Lane","year":"2020","journal-title":"medRxiv"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720324567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720324567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:32:27Z","timestamp":1759692747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720324567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":52,"alternative-id":["S0306987720324567"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110198","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"It is time to drop hydroxychloroquine from our COVID-19 armamentarium","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110198"}}